BioLineRx Ltd. filed a Form 6-K on November 18, 2026, disclosing that the company entered into a Purchase and Sale Agreement on November 17, 2026, to sell 80% of its future royalty rights on net sales of APHEXDA (motixafortide) to SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, L.P., for a one-time purchase price of $5.6 million.
Key Highlights
- Royalty sale: BioLineRx agreed to sell 80% of future royalty payments under its Ayrmid License, corresponding to a 14.4% royalty on net sales of APHEXDA, to SCOF Motixafortide Holdings, Inc.
- Purchase price: The Purchaser will pay a one-time price of $5.6 million at closing, less the Purchaser's documented reasonable transaction expenses capped at $100,000.
- Retained interest: BioLineRx will retain 20% of royalty payments, equating to a 3.6% royalty on net sales, which the filing states is attributable to obligations owed to Biokine Therapeutics Ltd.
- Loan prepayment: In connection with the transaction, BioLineRx will make a partial loan prepayment of $3.0 million to Kreos Capital VII Aggregator SCSp, with approximately $2.0 million remaining outstanding.
- Covenant removal: Following the prepayment, the minimum cash balance covenant of $4.0 million under the Loan Agreement will be eliminated, according to the filing.
- Expected closing: The transaction is expected to close on or about November 30, 2026, subject to customary closing conditions.
- Advisory fee: Chardan Capital Markets, LLC acted as financial advisor and will receive a fee of approximately $0.4 million upon closing.
BioLineRx Monetizes APHEXDA Royalties in Deal with Soleus Capital Affiliate
According to the Form 6-K filed with the SEC on November 18, 2026, BioLineRx Ltd. (NASDAQ:BLRX) entered into the Purchase Agreement with SCOF Motixafortide Holdings, Inc. on November 17, 2026. Under the agreement, the company agreed to sell 80% of its royalty payments receivable under its License Agreement with Ayrmid Pharma Ltd., dated November 20, 2024, as amended. The filing states that the 18% royalty rate payable to BioLineRx under the Ayrmid License results in the 80% interest corresponding to a 14.4% royalty on net sales of APHEXDA, with the retained 20% corresponding to a 3.6% royalty on net sales.
As a condition to closing, Ayrmid will consent to the sale and agree to remit the Purchased Receivables directly to the Purchaser, the filing disclosed. BioLineRx will retain all rights to receive potential future milestone payments under the Ayrmid License. In connection with the transaction, Kreos Capital VII Aggregator SCSp, described in the filing as an affiliate of BlackRock and the lender under BioLineRx's loan agreement dated September 14, 2022, consented to release its security interest in the Purchased Receivables. At closing, BioLineRx and Kreos will enter into a Second Amendment to the Loan Agreement, under which BioLineRx will make a $3.0 million partial prepayment, leaving approximately $2.0 million outstanding to be repaid under a new schedule.
The filing states that the company intends to use net proceeds to support ongoing research and development activities, "including the clinical development of GLIX1," as well as for working capital, general corporate purposes, and the partial loan repayment described above. The filing also notes that the press release issued on November 18, 2026 was titled "BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital."
What Was Disclosed
BioLineRx disclosed the terms of a royalty monetization agreement with a Soleus Capital affiliate, including the sale price, retained royalty interest, associated loan prepayment obligations, elimination of a cash covenant, and planned use of proceeds from the transaction.





Please wait processing your request...